HMN-214

Ref. 3D-FH170580

Informations sur le produit

• Nom: HMN-214
• Marque: Biosynth
• Description: HMN-214 is a novel oral prodrug that is being developed as a single agent therapy for the treatment of cancer. HMN-214 is a prodrug of the natural product dihydromyricetin, which inhibits mitochondrial complex I and II. HMN-214 has shown potent antitumor activity in tumor xenografts and demonstrated safety profile in vivo. The drug also induces cancer cell death via a mechanism that involves inhibition of kinase domain phosphorylation, leading to apoptosis induction. HMN-214 has been tested in vitro and in vivo for pharmacokinetics and gene expression profiling with promising results.

Propriétés chimiques

• Masse moléculaire: 424.47 g/mol
• Formule: C₂₂H₂₀N₂O₅S
• Degré de pureté: Min. 95%